StreetInsider.com News Articles

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Taylor Andrew Lawrence

Fri, 28 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26998160.html

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Taylor Andrew Lawrence

Fri, 28 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26998160.html

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Sherman Darren

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998111.html

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Sherman Darren

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998111.html

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Aiello Joshua

Fri, 28 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26998071.html

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Aiello Joshua

Fri, 28 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26998071.html

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 27 Aug 2026 08:30:00 -0400

NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day.

About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 27 Aug 2026 08:30:00 -0400

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 27 Aug 2026 08:30:00 -0400

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 27 Aug 2026 08:30:00 -0400

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Pacitti David

Fri, 14 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26931086.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Pacitti David

Fri, 14 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26931086.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Fain Eric S

Fri, 14 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26931060.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Fain Eric S

Fri, 14 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26931060.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Mack John Prosper

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26930950.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Mack John Prosper

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26930950.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Cleary Chris

Fri, 14 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26930909.html

Form 4 Orchestra BioMed Holding For: Aug 12 Filed by: Cleary Chris

Fri, 14 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26930909.html

Orchestra BioMed Inc. (OBIO) PT Raised to $10 at Piper Sandler

Tue, 11 Aug 2026 07:48:40 -0400

Piper Sandler analyst Matt O'Brien raised the price target on Orchestra BioMed Inc. (NASDAQ: OBIO) to $10.00 (from $9.00) while maintaining a Overweight rating.

Orchestra BioMed (OBIO) Tops Q2 EPS by 1c

Mon, 10 Aug 2026 18:19:11 -0400

Orchestra BioMed (NASDAQ: OBIO) reported Q2 EPS of ($0.38), $0.01 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on Orchestra BioMed (OBIO) click here.

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both